CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Knowing your stage will help the doctor decide what treatment, if any, you need. Most blood cancer doctors in the United States determine the stage of a patient’s CLL based on the Rai system. It divides CLL into five stages – 0 through IV. The higher the stage, the more enlarged ...
Choose a patient type: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Acute Myeloid Leukemia (AML) (US-VEN-240075) Important Safety Information & Indications Indications VENCLEXTA is indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or sma...
6. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq. Accessed May 2022. 7. ClinicalTrials.gov. ELEVATE CLL TN: S...
Important Safety Information Prescribing Information Not an actual patient. Newly diagnosed withMCL? CALQUENCE in combination with bendamustine and rituximab (BR)isnow approvedfor adults who have not had prior treatment for MCL and who cannot receive a type of stem cell transplant that uses their own...
EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors EP: 8.Navigating CLL Treatment Choices EP: 9.Therapy Sequencing in CLL EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors EP: 11.MCL Therapy Selection and Sequencing EP: 12.Impact of Patient-Re...
Treatment protocols for chronic lymphocytic leukemia (CLL) are provided below, including the following:Treatment for symptomatic disease Various single-agent and combination regimens Special considerations for treatment Response assessment Patients with low-risk (formerly Rai stage 0; Binet stage A) ...
Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.
[6]. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version.https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq. AccessedMay 2022. [7]. ClinicalTrials.gov. ELEVATE CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzum...
Dr Ahmed on Challenges Treating Patients With R/R LBCL Following Exposure to CAR T-Cell Therapy Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in...